FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065507003> ?p ?o ?g. }

• W2065507003 endingPage "484" @default.
• W2065507003 startingPage "470" @default.
• W2065507003 abstract "3-<i>tert</i>-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1<i>H</i>-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-<i>d</i>][1,2,4]triazine (MRK-016) is a pyrazolotriazine with an affinity of between 0.8 and 1.5 nM for the benzodiazepine binding site of native rat brain and recombinant human α1-, α2-, α3-, and α5-containing GABA_A receptors. It has inverse agonist efficacy selective for the α5 subtype, and this α5 inverse agonism is greater than that of the prototypic α5-selective compound 3-(5-methylisoxazol-3-yl)-6-[(1-methyl-1,2,3-triazol-4-hdyl)methyloxy]-1,2,4-triazolo[3,4-<i>a</i>]phthalazine (α5IA). Consistent with its greater α5 inverse agonism, MRK-016 increased long-term potentiation in mouse hippocampal slices to a greater extent than α5IA. MRK-016 gave good receptor occupancy after oral dosing in rats, with the dose required to produce 50% occupancy being 0.39 mg/kg and a corresponding rat plasma EC₅₀ value of 15 ng/ml that was similar to the rhesus monkey plasma EC₅₀ value of 21 ng/ml obtained using [¹¹C]flumazenil positron emission tomography. In normal rats, MRK-016 enhanced cognitive performance in the delayed matching-to-position version of the Morris water maze but was not anxiogenic, and in mice it was not proconvulsant and did not produce kindling. MRK-016 had a short half-life in rat, dog, and rhesus monkey (0.3–0.5 h) but had a much lower rate of turnover in human compared with rat, dog, or rhesus monkey hepatocytes. Accordingly, in human, MRK-016 had a longer half-life than in preclinical species (∼3.5 h). Although it was well tolerated in young males, with a maximal tolerated single dose of 5 mg corresponding to an estimated occupancy in the region of 75%, MRK-016 was poorly tolerated in elderly subjects, even at a dose of 0.5 mg, which, along with its variable human pharmacokinetics, precluded its further development." @default.
• W2065507003 created "2016-06-24" @default.
• W2065507003 creator A5002264412 @default.
• W2065507003 creator A5008391164 @default.
• W2065507003 creator A5019447711 @default.
• W2065507003 creator A5022393028 @default.
• W2065507003 creator A5026257303 @default.
• W2065507003 creator A5027021273 @default.
• W2065507003 creator A5027646929 @default.
• W2065507003 creator A5028370411 @default.
• W2065507003 creator A5028997463 @default.
• W2065507003 creator A5032877342 @default.
• W2065507003 creator A5032921714 @default.
• W2065507003 creator A5034485969 @default.
• W2065507003 creator A5040278333 @default.
• W2065507003 creator A5046453997 @default.
• W2065507003 creator A5055238379 @default.
• W2065507003 creator A5055488311 @default.
• W2065507003 creator A5055694926 @default.
• W2065507003 creator A5059535143 @default.
• W2065507003 creator A5068059585 @default.
• W2065507003 creator A5071764366 @default.
• W2065507003 creator A5072439028 @default.
• W2065507003 creator A5073141028 @default.
• W2065507003 creator A5079013738 @default.
• W2065507003 creator A5088268787 @default.
• W2065507003 date "2009-08-24" @default.
• W2065507003 modified "2023-09-26" @default.
• W2065507003 title "In Vitro and in Vivo Properties of 3-<i>tert</i>-Butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1<i>H</i>-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-<i>d</i>]-[1,2,4]triazine (MRK-016), a GABA_A Receptor α5 Subtype-Selective Inverse Agonist" @default.
• W2065507003 cites W152943885 @default.
• W2065507003 cites W1967445277 @default.
• W2065507003 cites W1983404085 @default.
• W2065507003 cites W1996107091 @default.
• W2065507003 cites W2001619275 @default.
• W2065507003 cites W2010532438 @default.
• W2065507003 cites W2016652516 @default.
• W2065507003 cites W2018461271 @default.
• W2065507003 cites W2029703893 @default.
• W2065507003 cites W2033005537 @default.
• W2065507003 cites W2035121432 @default.
• W2065507003 cites W2036204342 @default.
• W2065507003 cites W2039738625 @default.
• W2065507003 cites W2040188332 @default.
• W2065507003 cites W2042887680 @default.
• W2065507003 cites W2055569334 @default.
• W2065507003 cites W2056455169 @default.
• W2065507003 cites W2058342217 @default.
• W2065507003 cites W2070501236 @default.
• W2065507003 cites W2072498594 @default.
• W2065507003 cites W2083623577 @default.
• W2065507003 cites W2085277836 @default.
• W2065507003 cites W2087176798 @default.
• W2065507003 cites W2087519774 @default.
• W2065507003 cites W2095043290 @default.
• W2065507003 cites W2097643979 @default.
• W2065507003 cites W2099700185 @default.
• W2065507003 cites W2101030003 @default.
• W2065507003 cites W2106292851 @default.
• W2065507003 cites W2112877462 @default.
• W2065507003 cites W2121060688 @default.
• W2065507003 cites W2143086898 @default.
• W2065507003 cites W2151414518 @default.
• W2065507003 cites W2165223719 @default.
• W2065507003 cites W2169205273 @default.
• W2065507003 cites W2203342607 @default.
• W2065507003 doi "https://doi.org/10.1124/jpet.109.157636" @default.
• W2065507003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19704033" @default.
• W2065507003 hasPublicationYear "2009" @default.
• W2065507003 type Work @default.
• W2065507003 sameAs 2065507003 @default.
• W2065507003 citedByCount "61" @default.
• W2065507003 countsByYear W20655070032012 @default.
• W2065507003 countsByYear W20655070032013 @default.
• W2065507003 countsByYear W20655070032015 @default.
• W2065507003 countsByYear W20655070032016 @default.
• W2065507003 countsByYear W20655070032017 @default.
• W2065507003 countsByYear W20655070032018 @default.
• W2065507003 countsByYear W20655070032019 @default.
• W2065507003 countsByYear W20655070032020 @default.
• W2065507003 countsByYear W20655070032021 @default.
• W2065507003 countsByYear W20655070032022 @default.
• W2065507003 countsByYear W20655070032023 @default.
• W2065507003 crossrefType "journal-article" @default.
• W2065507003 hasAuthorship W2065507003A5002264412 @default.
• W2065507003 hasAuthorship W2065507003A5008391164 @default.
• W2065507003 hasAuthorship W2065507003A5019447711 @default.
• W2065507003 hasAuthorship W2065507003A5022393028 @default.
• W2065507003 hasAuthorship W2065507003A5026257303 @default.
• W2065507003 hasAuthorship W2065507003A5027021273 @default.
• W2065507003 hasAuthorship W2065507003A5027646929 @default.
• W2065507003 hasAuthorship W2065507003A5028370411 @default.
• W2065507003 hasAuthorship W2065507003A5028997463 @default.
• W2065507003 hasAuthorship W2065507003A5032877342 @default.
• W2065507003 hasAuthorship W2065507003A5032921714 @default.
• W2065507003 hasAuthorship W2065507003A5034485969 @default.
• W2065507003 hasAuthorship W2065507003A5040278333 @default.
• W2065507003 hasAuthorship W2065507003A5046453997 @default.
• W2065507003 hasAuthorship W2065507003A5055238379 @default.

• next